Combination of HDAC and topoisomerase inhibitors in small cell lung cancer

od Gray, Jhanelle, Cubitt, Christopher L., Zhang, Shumin, Chiappori, Alberto
Izdano 2012

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

od Turner, Joel G., Dawson, Jana, Cubitt, Christopher L., Baz, Rachid, Sullivan, Daniel M.
Izdano 2014

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

od Welch, Darcy, Kahen, Elliot, Fridley, Brooke, Brohl, Andrew S., Cubitt, Christopher L., Reed, Damon R.
Izdano u PLoS One (2019)

MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines

od Almhanna, Khaldoun, Cubitt, Christopher L, Zhang, Shumin, Kazim, Sabiha, Husain, Kazim, Sullivan, Dan, Sebti, Said, Malafa, Mokenge
Izdano 2013

Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma

od Kahen, Elliot, Yu, Diana, Harrison, Douglas J., Clark, Justine, Hingorani, Pooja, Cubitt, Christopher L., Reed, Damon R.
Izdano u Cancer Chemother Pharmacol (2016)

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

od Turner, Joel G., Dawson, Jana, Emmons, Michael F., Cubitt, Christopher L., Kauffman, Michael, Shacham, Sharon, Hazlehurst, Lori A., Sullivan, Daniel M.
Izdano 2013

Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma

od Yu, Diana, Kahen, Elliot, Cubitt, Christopher L., McGuire, Jeremy, Kreahling, Jenny, Lee, Jae, Altiok, Soner, Lynch, Conor C., Sullivan, Daniel M., Reed, Damon R.
Izdano u Sci Rep (2015)

Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival

od Tang, Chih-Hang Anthony, Ranatunga, Sujeewa, Kriss, Crystina L., Cubitt, Christopher L., Tao, Jianguo, Pinilla-Ibarz, Javier A., Del Valle, Juan R., Hu, Chih-Chi Andrew
Izdano 2014

Melphalan and exportin 1 inhibitors exert synergistic anti-tumor effects in preclinical models of human multiple myeloma

od Turner, Joel G., Cui, Yan, Bauer, Alexis A., Dawson, Jana L., Gomez, Juan A., Kim, Jongphil, Cubitt, Christopher L., Nishihori, Taiga, Dalton, William S., Sullivan, Daniel M.
Izdano u Cancer Res (2020)

Rapid Screening of Novel Agents for Combination Therapy in Sarcomas

od Cubitt, Christopher L., Menth, Jiliana, Dawson, Jana, Martinez, Gary V., Foroutan, Parastou, Morse, David L., Bui, Marilyn M., Letson, G. Douglas, Sullivan, Daniel M., Reed, Damon R.
Izdano 2013

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors conta...

od Garrett, Christopher R., Coppola, Domenico, Wenham, Robert M., Cubitt, Christopher L., Neuger, Anthony M., Frost, Timothy J., Lush, Richard M., Sullivan, Daniel M., Cheng, Jin Q., Sebti, Saïd M.
Izdano u Invest New Drugs (2010)

Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining T(reg) and antitumor CTL function

od Betts, Brian C., Veerapathran, Anandharaman, Pidala, Joseph, Yang, Hua, Horna, Pedro, Walton, Kelly, Cubitt, Christopher L., Gunawan, Steven, Lawrence, Harshani R., Lawrence, Nicholas J., Sebti, Said M., Anasetti, Claudio
Izdano u Sci Transl Med (2017)

Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors

od Kahen, Elliot John, Brohl, Andrew, Yu, Diana, Welch, Darcy, Cubitt, Christopher L., Lee, Jae K., Chen, Yunyun, Yoder, Sean J., Teer, Jamie K., Zhang, Yonghong O., Wallace, Margaret R., Reed, Damon R.
Izdano u Oncotarget (2018)

Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia

od Sweet, Kendra, Komrokji, Rami, Padron, Eric, Cubitt, Christopher L., Turner, Joel G., Zhou, Junmin, List, Alan F., Sallman, David A., Dawson, Jana L., Sullivan, Daniel M., Chavez, Julio, Shah, Bijal D., Lancet, Jeffrey E.
Izdano u Clin Cancer Res (2019)

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases

od Schonbrunn, Ernst, Betzi, Stephane, Alam, Riazul, Martin, Mathew P., Becker, Andreas, Han, Huijong, Francis, Rawle, Chakrasali, Ramappa, Jakkaraj, Sudhakar, Kazi, Aslamuzzaman, Sebti, Said M., Cubitt, Christopher L., Gebhard, Anthony W., Hazlehurst, Lori A., Tash, Joseph S., Georg, Gunda I.
Izdano 2013

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

od MARCHION, DOUGLAS C., BICAKU, ELONA, XIONG, YIN, ZGHEIB, NADIM BOU, SAWAH, ENTIDHAR AL, STICKLES, XIAOMANG BA, JUDSON, PATRICIA L., LOPEZ, ALEX S., CUBITT, CHRISTOPHER L., GONZALEZ-BOSQUET, JESUS, WENHAM, ROBERT M., APTE, SACHIN M., BERGLUND, ANDERS, LANCASTER, JOHNATHAN M.
Izdano u Oncol Rep (2013)

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer

od ZGHEIB, NADIM BOU, XIONG, YIN, MARCHION, DOUGLAS C., BICAKU, ELONA, CHON, HYE SOOK, STICKLES, XIAOMANG BA, AL SAWAH, ENTIDHAR, JUDSON, PATRICIA L., HAKAM, ARDESHIR, GONZALEZ-BOSQUET, JESUS, WENHAM, ROBERT M., APTE, SACHIN M., CUBITT, CHRISTOPHER L., CHEN, DUNG TSA, LANCASTER, JOHNATHAN M.
Izdano 2012

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival

od BUSH, STEPHEN H., TOLLIN, SHARON, MARCHION, DOUGLAS C., XIONG, YIN, ABBASI, FOROUGH, RAMIREZ, INGRID J., ZGHEIB, NADIM BOU, BOAC, BERNADETTE, JUDSON, PATRICIA L., CHON, HYE SOOK, WENHAM, ROBERT M., APTE, SACHIN M., CUBITT, CHRISTOPHER L., BERGLUND, ANDERS E., HAVRILESKY, LAURA J., LANCASTER, JOHNATHAN M.
Izdano u Mol Clin Oncol (2016)